NEW YORK – Belgian molecular diagnostics firm Biocartis said on Tuesday it has signed a license, development, and commercialization agreement with startup GeneproDx to develop GeneproDx's ThyroidPrint on Biocartis' Idylla platform, as well as a separate agreement with Endpoint Health to develop and commercialize a novel companion diagnostic (CDx) test on the Idylla instrument.
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.
Don't have a 360Dx or GenomeWeb account?
Register for Free.